클로르페니라민(Chlorpheniramine maleate)

관리자
2021-04-30
조회수 126

▪ 약물의 분류: 항히스타민제▪ 임신부 약물등급(US FDA): B

▪ 임신부 안전 및 기형발생정보Based on experimental animal studies, chlorpheniramine is not expected to increase the risk of malformations. Human studies have suggested associations with some birth defects.

▪ 모유수유부 약물등급(Medication and Mother’s MilK): L3

▪ 모유수유 안전 및 유해성정보No adverse effects were noted among 5 infants exposed to cholorpheniramine in human milk. For a discussion of the use of other antihistamines while breastfeeding, see Brompheniramine.

▪ 한국마더세이프전문상담센터 DB 정보 (모태독성학2016):

1) 기형발생정보
클로르페니라민에 노출된 후 추적된 임신부는 총 1,391례이었으며 초기 노출 후 자연유산율은 5.1%(71/1,391)이었다. 임신 37주 이전의 조산률은 4.2%(40/959), 2,500 g 미만의 저체중증은
2.7%(26/953)이었다.
주요기형발생은 2.6%(25/953): unilateral cleft lip and palate left side with bilateral clenched hands/ventricular septal defect(1), PDA(3), smooth philtrum with thin upper lip with left ear microtia(1), bilateral inguinal hernia(1), fetal right renal cyst(1), cyst in caudothalamic groove(1), right UPJ stenosis with right scrotal hydrocele(1), dysplastic kidncy(1), left with megaureter(1),
nasolacrimal duct obstruction with ptosis(1), hydrocele and left wrist drop(1), imperforate anus(1), hydronephrosis(1), MCDK(1),m right liver mass(1), ASD with small PDA(1), ASD(1), VSD(1), microtia with invisible external ear orfice(1), right inguinal hernia(1), CCAM(1), cleft palate(1), undefined major anomaly(1), right hydronephrosis(1)가 있었다. 그리고 사산 4례가 있었다.

2) 모유 수유 시 독성 및 적합성 정보
수유부-수유아 27쌍 중 젖양감소 1례가 있었다.

0 0

사단법인 임산부약물정보센터



(사)임산부약물정보센터 (대표자: 한정열)
서울 중구 퇴계로50길 12-1 2층 | 02-2272-4737
Copyright© 2021 Korean Mothersafe Professional Counseling Center. All Rights Reserved